Prostatype Genomics AB (publ) (PROGEN.ST)

SEK 1.87

(-2.09%)

Operating Expenses Summary of Prostatype Genomics AB (publ)

Prostatype Genomics AB (publ)'s latest annual operating expenses in 2023 was 3.22 Million SEK , down -89.02% from previous year.
Prostatype Genomics AB (publ)'s latest quarterly operating expenses in 2024 Q2 was 4.73 Million SEK , down 0.0% from previous quarter.
Prostatype Genomics AB (publ) reported a annual operating expenses of 29.37 Million SEK in annual operating expenses 2022, up 62.66% from previous year.
Prostatype Genomics AB (publ) reported a annual operating expenses of 18.05 Million SEK in annual operating expenses 2021, up 647.98% from previous year.
Prostatype Genomics AB (publ) reported a quarterly operating expenses of 4.73 Million SEK for 2024 Q1, down -33.58% from previous quarter.
Prostatype Genomics AB (publ) reported a quarterly operating expenses of 8.18 Million SEK for 2023 Q1, down -3.06% from previous quarter.

Annual Operating Expenses Chart of Prostatype Genomics AB (publ) (2023 - 2015)

Historical Annual Operating Expenses of Prostatype Genomics AB (publ) (2023 - 2015)

Year	Operating Expenses	Operating Expenses Growth
2023	3.22 Million SEK	-89.02%
2022	29.37 Million SEK	62.66%
2021	18.05 Million SEK	647.98%
2020	2.41 Million SEK	0.0%
2018	11.17 Million SEK	-20.14%
2017	13.98 Million SEK	200.47%
2016	4.65 Million SEK	-12.74%
2015	5.33 Million SEK	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	4.73 Million SEK	0.0%
2024 Q1	4.73 Million SEK	-33.58%
2023 Q1	8.18 Million SEK	-3.06%
2023 FY	3.22 Million SEK	-89.02%
2023 Q2	10.11 Million SEK	23.55%
2023 Q3	7.12 Million SEK	-29.5%
2023 Q4	7.12 Million SEK	0.0%
2022 FY	29.37 Million SEK	62.66%
2022 Q4	8.44 Million SEK	8.92%
2022 Q3	7.75 Million SEK	5.02%
2022 Q2	7.38 Million SEK	27.31%
2022 Q1	5.79 Million SEK	-10.38%
2021 Q1	4.19 Million SEK	143.34%
2021 FY	18.05 Million SEK	647.98%
2021 Q4	6.46 Million SEK	59.25%
2021 Q3	4.06 Million SEK	40.13%
2021 Q2	2.89 Million SEK	-30.89%
2020 FY	2.41 Million SEK	0.0%
2020 Q4	1.72 Million SEK	-56.33%
2020 Q3	3.94 Million SEK	12.88%
2020 Q2	3.49 Million SEK	55.23%
2020 Q1	2.25 Million SEK	44.67%
2019 Q4	1.55 Million SEK	676.85%
2019 Q3	200.43 Thousand SEK	0.0%
2018 FY	11.17 Million SEK	-20.14%
2017 FY	13.98 Million SEK	200.47%
2016 FY	4.65 Million SEK	-12.74%
2015 FY	5.33 Million SEK	0.0%

Peer Operating Expenses Comparison of Prostatype Genomics AB (publ)

Name	Operating Expenses	Operating Expenses Difference
AroCell AB (publ)	57.68 Million SEK	94.409%
Devyser Diagnostics AB (publ)	204.6 Million SEK	98.424%
Immunovia AB (publ)	291.35 Million SEK	98.893%
SenzaGen AB	49.67 Million SEK	93.507%
Spermosens AB	10.72 Million SEK	69.93%